Hybrid Skin Booster · PDLLA + HA
JUVELOOK in Seoul
PDLLA + HA
JUVELOOK combines poly-D,L-lactic acid (PDLLA) with hyaluronic acid (HA). Delight Dermatology in Seoul offers JUVELOOK skin-booster treatment, with product selection and follow-up discussed during consultation.
Board-Certified Dermatologist
Dr. SangYoul Yun
AAD International Fellow
IFAAD
- Duration
- 20-30 min (per area, full face); cannula technique for periorbital adds ~10 min
- Sessions
- 3 induction (~1 month / 4 wk apart); maintenance not yet standardized (>12 mo data not published)
- Downtime
- ~1 week swelling resolution
JUVELOOK Treatment in Seoul
- Duration
- 20–30 min per area (full face)
- Sessions
- 3 induction (3–6 wk); maintenance not yet standardized
- Downtime
- ~1 week swelling resolution
- Response review
- Assess response at follow-up; timing varies by treatment area and individual response.
Results Over Time
A 2025 study evaluated JUVELOOK for tear-trough concerns in Korean women, with follow-up at one week, one month and six months. Those observation points do not establish when every patient will see a result.
1Before treatment
Discuss the treatment area, number of sessions, risks and follow-up before booking.
2After injection
Swelling and bruising can occur after injection. Their duration varies.
3Follow-up
Assess response at follow-up; timing varies by treatment area and individual response.
4Evidence
A 2025 study evaluated JUVELOOK for tear-trough concerns in Korean women, with follow-up at one week, one month and six months. Those observation points do not establish when every patient will see a result.
5Further treatment
Discuss the treatment area, number of sessions, risks and follow-up before booking.
JUVELOOK Skin Booster
JUVELOOK is a PDLLA + HA product made by VAIM. The skin-booster formulation and JUVELOOK Volume are distinct options; confirm which product is proposed for the treatment area.
PDLLA + HA Hybrid
JUVELOOK is a PDLLA + HA product made by VAIM. The skin-booster formulation and JUVELOOK Volume are distinct options; confirm which product is proposed for the treatment area.
Small, Spherical Particles
Small, round biodegradable microspheres that the body gradually breaks down.
Base vs Volume
Base JUVELOOK for superficial/mid-dermal boosting; JUVELOOK Volume (LENISNA) with ~4× PDLLA for deeper volumization.
Treatment Process
1Clinical Assessment
The dermatologist assesses skin concerns, goals, and history: checking lidocaine sensitivity, retinoid use, and nearby infection or dental work.
2Product Selection
Base JUVELOOK (superficial/mid-dermis) vs JUVELOOK Volume / LENISNA (deeper volumization, ~4× higher PDLLA dose).
3Reconstitution
Same-day reconstitution is permitted by manufacturer protocol, shorter than Sculptra historically required.
4Procedural Safety
Topical anesthesia applied; cannula strongly preferred for the tear trough and high-vascular-risk areas.
Treatment explained
How JUVELOOK is injected into the cheek dermis
Juvelook contains PDLLA and hyaluronic acid.
Film guide (1–9)
What the numbers show
- 1. Cheek · example injection area
- 2. Injection point on the cheek
- 3. Fine needle
- 4. Epidermis
- 5. Dermis
- 6. Subcutaneous fat
- 7. Muscle layer
- 8. Injection site
- 9. Injection site in the dermis
In the film
- Injections are spread across several points in the cheek's dermis.
- A fine needle enters the skin.
- The needle tip sits in the dermis.
- The injection is given at each point.
Recovery & Care
First 24–48h
Avoid heat, exercise, and facial massage. Call the clinic for severe pain, vision change, or color change.
Day 3–7
Resume normal skincare. Avoid retinoids until skin settles. SPF 50+.
Week 2–4
Schedule the next session per the induction protocol. Strict sun protection.
Long-term
Daily SPF 50+. Report any persistent nodule promptly.
Frequently Asked Questions
Q.How much does JUVELOOK cost in Korea?
Delight Dermatology in Gangnam, Seoul publishes these prices in Korean won: JuveLook Skin Booster 3cc, KRW 150,000–300,000 per session; Delight JuveLook Booster 4cc, KRW 200,000–350,000 per session (premium 4cc). The itemized quote follows the examination and depends on the treatment area, amount and plan.
Q.Is JUVELOOK FDA-approved?
No. JUVELOOK is NOT cleared by the US FDA as an injectable. It is MFDS-approved as a medical device in Korea (since approximately 2021) and CE-marked in the EU. Several Gangnam clinic marketing pages incorrectly claim FDA approval, likely confusion with Sculptra (PLLA, manufactured by Galderma), which is FDA-approved and is a different molecule (L-isomer only, not the D,L racemic mixture in JUVELOOK). Honest regulatory framing is part of board-certified Anti-Aging specialist standards.
Q.Which product and variant does this page describe?
JUVELOOK is a PDLLA + HA product made by VAIM. The skin-booster formulation and JUVELOOK Volume are distinct options; confirm which product is proposed for the treatment area.
Q.What does the cited evidence establish about timing?
A 2025 study evaluated JUVELOOK for tear-trough concerns in Korean women, with follow-up at one week, one month and six months. Those observation points do not establish when every patient will see a result.
Q.What are the most serious risks?
Rare but serious: vascular occlusion, including blindness, from inadvertent intravascular injection, particularly in glabellar, periorbital, and forehead zones. The Lau 2025 expert consensus on PDLLA-HA200-induced visual impairment (PMID 41359890) is the authoritative safety document; clinic protocol should reflect its key safe-injection messages (cannula for high-risk zones, hyaluronidase emergency kit, anatomy-based depth control). Common transient risks include swelling, bruising, and mild erythema (~7-43% across published series); rare late-onset nodules have been documented. One published JUVELOOK tear-trough nodule case fully resolved with monopolar RF (Seo 2024, PMID 39283001).
Q.What must be confirmed before booking?
Discuss the treatment area, number of sessions, risks and follow-up before booking.
References6
The clinical claims on this page (device specs, efficacy timelines, safety profile) are supported by the primary sources below. Each citation links to the original paper or regulatory record.
- [1]Hybrid PDLLA-HA for Tear Trough Rejuvenation. Aesthetic Plast Surg (Young & Lau): prospective study N=15 (2026).
- [2]Safe Injection Technique for PDLLA-HA200 (Visual Impairment Consensus). J Craniofac Surg (Lau et al.): authoritative safety consensus (2025).
- [3]PDLLA for Lower Eyelid Rejuvenation: Efficacy and Safety. J Cosmet Dermatol (Wan et al.): tear-trough series, 6-month follow-up (2025).
- [4]Microneedling + Topical PDLLA for Pore + Texture Improvement. Plast Reconstr Surg Glob Open (Wan et al.): N=15, 22-week follow-up (2025).
- [5]PLLA vs PDLLA Fillers: Comparative Mouse Study. In Vivo (Jang et al.): independent SNU/Sookmyung comparator (2026).
- [6]Energy-Based Management of PDLLA Tear-Trough Nodule. J Cosmet Dermatol (Seo et al.): RF rescue case report (2024).
Notice
- Pregnancy or breastfeeding
- Active skin infection or HSV at injection site
- Known hypersensitivity to lidocaine or product components
- Active autoimmune flare or history of granuloma with biostimulators: needs clearance
- Recent permanent filler or oral retinoid in the same zone: timing reviewed at consultation
- Anticoagulant medication: physician clearance and bruising risk discussed
Session summary & comparison
| Item | Details |
|---|---|
| Treatment time | About 20-30 minutes per area; the cannula technique for the tear trough and periorbital zone adds roughly 10 minutes |
| What it is | JUVELOOK is a PDLLA + HA product made by VAIM. The skin-booster formulation and JUVELOOK Volume are distinct options; confirm which product is proposed for the treatment area. |
| Course & onset | Assess response at follow-up; timing varies by treatment area and individual response. |
| Downtime | Around a week of mild swelling, with possible bruising; heat and exercise are best avoided for 24-48 hours |
| Regulatory status | juvelook: Regulatory status must be verified for the exact model and jurisdiction against an authoritative primary record. |
| Category | JUVELOOK | Rejuran | Sculptra | HA skin booster |
|---|---|---|---|---|
| Main material | PDLLA microspheres with hyaluronic acid | Polynucleotide (PDRN) from salmon DNA | Poly-L-lactic acid (PLLA) | Hyaluronic acid |
| What it does | JUVELOOK is a PDLLA + HA product made by VAIM. The skin-booster formulation and JUVELOOK Volume are distinct options; confirm which product is proposed for the treatment area. | Supports the skin's own repair and barrier quality | Long-acting collagen biostimulation for facial structure | Hydrates and improves skin quality |
| Onset of results | Assess response at follow-up; timing varies by treatment area and individual response. | Builds gradually over weeks | Develops over 3-6 months | Immediate hydration; does not build collagen |
| Sessions | 3, about 4 weeks apart | 3-4, at 2-4 week intervals | 2-3, over 4-6 weeks | A course, repeated as maintenance |
| Regulatory status | juvelook: Regulatory status must be verified for the exact model and jurisdiction against an authoritative primary record. | MFDS Class IV, CE-marked; not FDA-approved as an injectable | juvelook: Regulatory status must be verified for the exact model and jurisdiction against an authoritative primary record. | Varies by product |
Updated
Related procedures
Evidence & comparison guides
Need another answer before deciding?
You do not need to read every guide. Open the question that still matters to your decision.
Optional decision guides
- Interactive routeFit a dermatologist visit into your itineraryCompare a day trip, overnight visit, or longer stay by travel buffer and typical visible recovery.Open the trip planner →
- Comparison guideSculptra vs Skin Boosters Seoul | Evidence-Based GuideCompare Sculptra with Rejuran PN, Skinvive and Profhilo by treatment goal, published evidence, U.S. FDA status and practical questions to ask in Seoul.
Clinic articles
- Clinic articleIs Rejuran PN or PDRN? Evidence, FDA Status & Seoul GuideIs Rejuran FDA approved? Our 2026 search found no U.S. FDA authorization. What PN vs PDRN means, the published evidence, risks, and what to ask in Seoul.
- Clinic articleBuilding Collagen: Procedures vs Homecare: What Actually WorksA board-certified Seoul dermatologist separates evidence from marketing: which procedures and which skincare ingredients genuinely stimulate collagen, graded by clinical evidence.
Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.
Next Step